{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To evaluate the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant plus intranasal placebo in delaying relapse of depressive symptoms in subjects with treatment-resistant depression (TRD) who are in stable remission after an initial period of treatment with intranasal esketamine plus an oral antidepressant.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective",
        "text": "To evaluate the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant plus intranasal placebo in delaying relapse of depressive symptoms in subjects with TRD who are in stable response (but not stable remission) after an initial period of treatment with intranasal esketamine plus an oral antidepressant.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Safety Objective",
        "text": "To assess the long-term safety and tolerability of intranasal esketamine plus an oral antidepressant in subjects with TRD, including: Treatment-emergent adverse events (TEAEs), including AEs of special interest; Effects on heart rate and blood pressure; Effects on respiratory rate and pulse oximetry; Sensory-perceptual changes (eg, dissociation); Potential for treatment-emergent psychotic symptoms; Cognitive effects; Effects on mood (eg, induction of mania or hypomania); Potential for suicidal ideation and behavior; Potential for treatment-emergent cystitis and other urinary tract symptoms; Potential for withdrawal and rebound symptoms following esketamine discontinuation; Nasal tolerability.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "Time to relapse (for subjects in stable remission) during the maintenance phase.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Endpoint",
        "text": "Time to relapse (for subjects in stable response) during the maintenance phase.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Safety Endpoints",
        "text": "Incidence of TEAEs, changes in vital signs, Clinician-Administered Dissociative States Scale (CADSS), Brief Psychiatric Rating Scale (BPRS), Cogstate computerized cognitive battery, Young Mania Rating Scale (YMRS), Columbia-Suicide Severity Rating Scale (C-SSRS), and nasal tolerability assessments.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      }
    ],
    "estimands": [],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 2,
      "exploratoryObjectives": 0,
      "totalEndpoints": 3,
      "totalEstimands": 0
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To evaluate the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant plus intranasal placebo in delaying relapse of depressive symptoms in subjects with treatment-resistant depression (TRD) who are in stable remission after an initial period of treatment with intranasal esketamine plus an oral antidepressant.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective",
        "text": "To evaluate the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant plus intranasal placebo in delaying relapse of depressive symptoms in subjects with TRD who are in stable response (but not stable remission) after an initial period of treatment with intranasal esketamine plus an oral antidepressant.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Safety Objective",
        "text": "To assess the long-term safety and tolerability of intranasal esketamine plus an oral antidepressant in subjects with TRD, including: Treatment-emergent adverse events (TEAEs), including AEs of special interest; Effects on heart rate and blood pressure; Effects on respiratory rate and pulse oximetry; Sensory-perceptual changes (eg, dissociation); Potential for treatment-emergent psychotic symptoms; Cognitive effects; Effects on mood (eg, induction of mania or hypomania); Potential for suicidal ideation and behavior; Potential for treatment-emergent cystitis and other urinary tract symptoms; Potential for withdrawal and rebound symptoms following esketamine discontinuation; Nasal tolerability.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "Time to relapse (for subjects in stable remission) during the maintenance phase.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Endpoint",
        "text": "Time to relapse (for subjects in stable response) during the maintenance phase.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Safety Endpoints",
        "text": "Incidence of TEAEs, changes in vital signs, Clinician-Administered Dissociative States Scale (CADSS), Brief Psychiatric Rating Scale (BPRS), Cogstate computerized cognitive battery, Young Mania Rating Scale (YMRS), Columbia-Suicide Severity Rating Scale (C-SSRS), and nasal tolerability assessments.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      }
    ],
    "estimands": []
  }
}